Georgiana Toma: Why Nutrition is a Hematologist’s Secret Weapon
Georgiana Toma, Hematology Resident at Bucharest Emergency University Hospital, shared a post on LinkedIn:
“Nutrition is a Hematologist’s secret weapon
In my clinical days, the most common question I get isn’t about the latest monoclonal antibody. It’s: ‘Doctor, what should I eat to fix my blood?’
It’s a question born from a desire for agency—patients wanting to take part in their own recovery. And while ‘eating your greens’ is a start, hematology requires a much more strategic approach to the plate.
1. The Bioavailability Trap
We often treat iron deficiency anemia as a simple math problem:
Low iron benefits from iron-rich foods leads to success.
In reality, it’s more of a chemistry problem.
Many patients diligently consume iron-rich meals, but wash them down with coffee or tea. Polyphenols and phytates in these drinks can significantly reduce the absorption of non-heme iron, limiting the bioavailability of otherwise iron-rich meals.
Emerging research suggests that the gut microbiome may play an important role in modulating systemic iron homeostasis. A healthy gut ecosystem is not only essential for digestion—it may also influence effective erythropoiesis.
2. Nutrition as Adjuvant Therapy in Hematologic Malignancies
When dealing with leukemia, lymphoma, or multiple myeloma, nutrition shifts from ‘wellness advice’ to a genuine treatment-support strategy.
Cancer-related muscle wasting (cachexia) represents one of the most significant barriers to maintaining chemotherapy intensity and treatment tolerance. A high-protein, calorie-adequate diet is not about weight—it is about preserving the structural and metabolic reserves that allow patients to withstand full treatment cycles.
Emerging research is also exploring the gut–bone marrow axis, where microbial metabolites interact with immune pathways and hematopoiesis. Early data suggest that microbiome diversity may even influence responses to modern therapies, including immunotherapy and cellular therapies.
The bone marrow is one of the most metabolically active tissues in the body. As clinicians, we shouldn’t only treat the blood—we must also ensure that the factory producing it has the resources it needs to function.”
Stay updated with Hemostasis Today.
-
Mar 26, 2026, 16:56Anu Anna Babu: Which DOAC is Safer for Patients With Acute Venous Thromboembolism?
-
Mar 26, 2026, 16:39Faizan Khan: Cold Agglutinins and Their Effects on CBC Results
-
Mar 26, 2026, 16:38Strengthening Research and Partnerships at THSNA 2026 – NBDF
-
Mar 26, 2026, 16:38Gareth Owens: Advancing Patient Engagement in Cardiothoracic Surgery
-
Mar 26, 2026, 16:36Yan Leyfman: Episode 3 of The Translational Edge on Cancer Anticoagulation Is Now Live on Shuf
-
Mar 26, 2026, 15:50Vicky Kumar: How Best to Manage Patients with Patent Foramen Ovale After a Cryptogenic Stroke
-
Mar 26, 2026, 15:47Edward Lee Carter: Are All DOACs Truly Interchangeable in Real-World Practice?
-
Mar 26, 2026, 15:46Faizan Khan: Key Findings on Long Term Stroke Risk After TIA and Minor Stroke
-
Mar 26, 2026, 15:441 in 4 Will Have a Stroke, It is More Common than People Think and It Does Not Discriminate – European Stroke Organisation